Tempest Therapeutics, Inc.
TPST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28 | $17 | $23 | $17 |
| G&A Expenses | $14 | $12 | $12 | $10 |
| SG&A Expenses | $14 | $12 | $12 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $42 | $29 | $35 | $27 |
| Operating Income | -$42 | -$29 | -$35 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$1 | -$1 |
| Pre-Tax Income | -$42 | -$29 | -$36 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42 | -$29 | -$36 | -$28 |
| % Margin | – | – | – | – |
| EPS | -1.5 | -1.91 | -3.18 | -7.8 |
| % Growth | 21.5% | 39.9% | 59.2% | – |
| EPS Diluted | -1.5 | -1.91 | -3.18 | -7.8 |
| Weighted Avg Shares Out | 28 | 15 | 1 | 0 |
| Weighted Avg Shares Out Dil | 28 | 15 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $1 | $1 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$40 | -$28 | -$33 | -$27 |
| % Margin | – | – | – | – |